Tommy

“Just a quick pipeline question on Huntington. In the context of recent SIRNA data in the field, maybe speak to what you're targeting in terms of the HTT knockdown with SMP 105 and your confidence in the overall brain distribution and safety profile here.”

“Just a couple on the upcoming pain launch. Maybe could you speak to how hospital purchasing dynamics in ambulatory surgical centers are evolving under the No Pain Act?”

“I'm for Selvin, and congratulations on the progress here. Just a follow-up on that. When we're thinking about the PRNJ code, can you dissect a little bit more how much that factors into the 4Q revenue step-up versus new patient ads?”

“I'm curious if you could provide more detail. You spoke to the mechanisms behind, you know, driving increased diagnosis and switching for pompility unfold and for gallifold.”

“I'm curious on if you're seeing a slower rate of second-line patients, TAF progressors per year given trends in earlier diagnoses and potentially patients staying on TAF for longer?”